Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.

Latest Post

May 02, 2019

FDA Guidance Affecting cGMP Compounding Pharmacies (503Bs)

Since the 2012 New England Compounding Center tragedy that linked a deadly fungal meningitis outbreak to a failure to use current good manufacturing practices (cGMP),<sup>1</sup> compounding pharmacies have faced increasing scrutiny and regulation by the U.S. Food and Drug Administration (FDA). While registering with the FDA is still voluntary, only compounding pharmacies that register, and pass inspection, will be granted “503B” status as compounding outsourcing facilities under Section 503B of the Federal Food, Drug, and Cosmetic Act.<sup>2</sup>
Amy Kim

Amy Kim

Sr. Specialist, Scientific Communications, SA & TS


Search the Blog





  • Previous Posts
    SmartDose Injection Platform in Use

    October 16, 2018

    Medical Device User Fee Rates

    Ana Ladino

    Ana Ladino

    Director, Regulatory Affairs

    A girl smiling with her dog

    July 30, 2018

    FDA Guidance on Elemental Impurities Affects Animal Health Customers

    Kevin Cancelliere

    Kevin Cancelliere

    Director, Segment Marketing, Pharma

    Blue West logo with Diamond

    April 16, 2014

    New FDA Guidance Issued for Annual Reportable Changes

    Steve LoCastro

    Steve LoCastro

    Director, Regulatory Affairs

    Blue West logo with Diamond

    October 16, 2013

    Seeking Subvisible Particles

    West Pharma

    Whitney Winters

    Director, Sales, Emerging Biologics

    Load more